[{"id":"65a39e57-0fe4-43a3-8e14-9aae8f76d3a5","acronym":"","url":"https://clinicaltrials.gov/study/NCT06124157","created_at":"2023-11-09T16:12:44.229Z","updated_at":"2025-02-25T14:42:30.057Z","phase":"Phase 3","brief_title":"A Study Comparing the Combination of Dasatinib and Chemotherapy Treatment With or Without Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or Philadelphia Chromosome-Like (Ph-Like) ABL-Class B-Cell Acute Lymphoblastic Leukemia (B-ALL)","source_id_and_acronym":"NCT06124157","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" ABL1 • KIT • PDGFRA • CD19 • PDGFRB • CSF1R","pipe":" | ","alterations":" CD19 expression","tags":["ABL1 • KIT • PDGFRA • CD19 • PDGFRB • CSF1R"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e dasatinib • imatinib • cytarabine • doxorubicin hydrochloride • cyclophosphamide • Blincyto (blinatumomab) • methotrexate • vincristine • daunorubicin • leucovorin calcium • Oncaspar liquid (pegaspargase) • mercaptopurine • Asparlas (calaspargase pegol-mknl) • thioguanine • Starasid (cytarabine ocfosfate)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 680","initiation":"Initiation: 05/29/2025","start_date":" 05/29/2025","primary_txt":" Primary completion: 12/01/2030","primary_completion_date":" 12/01/2030","study_txt":" Completion: 12/01/2030","study_completion_date":" 12/01/2030","last_update_posted":"2025-02-14"},{"id":"4448c756-db79-4484-aae6-303e6174097b","acronym":"AALL1631","url":"https://clinicaltrials.gov/study/NCT03007147","created_at":"2021-01-18T14:47:39.557Z","updated_at":"2025-02-25T14:50:25.163Z","phase":"Phase 3","brief_title":"Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia","source_id_and_acronym":"NCT03007147 - AALL1631","lead_sponsor":"Children's Oncology Group","biomarkers":" ABL1 • BCR • PDGFRA • PDGFRB • IKZF1 • CSF1R","pipe":" | ","alterations":" BCR-ABL1 fusion • ABL1 fusion","tags":["ABL1 • BCR • PDGFRA • PDGFRB • IKZF1 • CSF1R"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCR-ABL1 fusion • ABL1 fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e imatinib • cytarabine • doxorubicin hydrochloride • cyclophosphamide • ifosfamide • etoposide IV • methotrexate • vincristine • daunorubicin • dexamethasone • leucovorin calcium • Oncaspar liquid (pegaspargase) • mercaptopurine delayed release (DR6MP) • mercaptopurine • Asparlas (calaspargase pegol-mknl) • thioguanine • Hemady (dexamethasone tablets) • Neupogen (filgrastim) • Starasid (cytarabine ocfosfate) • cyclophosphamide intravenous • dexrazoxane • levoleucovorin calcium • prednisolone"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 475","initiation":"Initiation: 08/08/2017","start_date":" 08/08/2017","primary_txt":" Primary completion: 09/30/2027","primary_completion_date":" 09/30/2027","study_txt":" Completion: 09/30/2027","study_completion_date":" 09/30/2027","last_update_posted":"2025-02-13"},{"id":"b88cc8bc-838d-43e3-8862-07db1c3a612f","acronym":"SWOG-S1318","url":"https://clinicaltrials.gov/study/NCT02143414","created_at":"2021-01-18T09:57:21.812Z","updated_at":"2025-02-25T16:36:22.860Z","phase":"Phase 2","brief_title":"Blinatumomab and Combination Chemotherapy or Dasatinib, Prednisone, and Blinatumomab in Treating Older Patients With Acute Lymphoblastic Leukemia","source_id_and_acronym":"NCT02143414 - SWOG-S1318","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" ABL1 • BCR • PDGFRA • FGFR • PDGFRB • CD4 • CSF1R","pipe":" | ","alterations":" ABL2 fusion","tags":["ABL1 • BCR • PDGFRA • FGFR • PDGFRB • CD4 • CSF1R"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ABL2 fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e dasatinib • Blincyto (blinatumomab) • methotrexate • vincristine • prednisone • mercaptopurine delayed release (DR6MP) • mercaptopurine • Xatmep (methotrexate oral solution)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 53","initiation":"Initiation: 06/30/2015","start_date":" 06/30/2015","primary_txt":" Primary completion: 06/01/2022","primary_completion_date":" 06/01/2022","study_txt":" Completion: 10/23/2025","study_completion_date":" 10/23/2025","last_update_posted":"2025-02-06"},{"id":"8f093304-44ac-4ac6-aa1f-9424e042581c","acronym":"","url":"https://clinicaltrials.gov/study/NCT02494882","created_at":"2021-01-18T12:01:48.985Z","updated_at":"2025-02-25T15:42:29.508Z","phase":"Phase 1","brief_title":"Adding Ruxolitinib to a Combination of Dasatinib Plus Dexamethasone in Remission Induction Therapy in Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Patients Aged 40 Years or Older","source_id_and_acronym":"NCT02494882","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" ABL1 • BCR • PDGFRB • CRLF2 • JAK3 • CSF1R • TSLP","pipe":" | ","alterations":" BCR-ABL1 E255K • BCR-ABL1 V299L • BCR-ABL1 F317L • ABL1 T315I • BCR-ABL1 L248V • BCR-ABL1 Q252H • BCR-ABL1 F317V • JAK3 mutation • ABL1 E255K • BCR-ABL1 F317C • BCR-ABL1 T315A • ABL1 F317L • BCR-ABL1 L248R","tags":["ABL1 • BCR • PDGFRB • CRLF2 • JAK3 • CSF1R • TSLP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCR-ABL1 E255K • BCR-ABL1 V299L • BCR-ABL1 F317L • ABL1 T315I • BCR-ABL1 L248V • BCR-ABL1 Q252H • BCR-ABL1 F317V • JAK3 mutation • ABL1 E255K • BCR-ABL1 F317C • BCR-ABL1 T315A • ABL1 F317L • BCR-ABL1 L248R"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e dasatinib • Jakafi (ruxolitinib) • dexamethasone"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 12","initiation":"Initiation: 06/29/2015","start_date":" 06/29/2015","primary_txt":" Primary completion: 06/01/2025","primary_completion_date":" 06/01/2025","study_txt":" Completion: 06/01/2025","study_completion_date":" 06/01/2025","last_update_posted":"2024-07-29"},{"id":"6d0b40ae-0057-41ed-9ea5-d6965f8e7aa0","acronym":"","url":"https://clinicaltrials.gov/study/NCT03238027","created_at":"2021-01-18T16:00:03.519Z","updated_at":"2024-07-02T16:35:03.052Z","phase":"Phase 1","brief_title":"A Phase 1 Study to Investigate Axatilimab Alone or in Combination With Durvalumab in Patients With Solid Tumors","source_id_and_acronym":"NCT03238027","lead_sponsor":"Syndax Pharmaceuticals","biomarkers":" PD-1 • IFNG • IL6 • TNFA • PD-L2 • IL2 • IL10 • CSF1R • IL1B • MSR1","pipe":"","alterations":" ","tags":["PD-1 • IFNG • IL6 • TNFA • PD-L2 • IL2 • IL10 • CSF1R • IL1B • MSR1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imfinzi (durvalumab) • Niktimvo (axatilimab-csfr)"],"overall_status":"Completed","enrollment":" Enrollment 45","initiation":"Initiation: 09/01/2017","start_date":" 09/01/2017","primary_txt":" Primary completion: 11/20/2020","primary_completion_date":" 11/20/2020","study_txt":" Completion: 11/20/2020","study_completion_date":" 11/20/2020","last_update_posted":"2024-05-17"},{"id":"bd0915a0-fd20-4277-b54e-97bf1a6410c3","acronym":"","url":"https://clinicaltrials.gov/study/NCT03452774","created_at":"2021-01-18T17:01:36.578Z","updated_at":"2024-07-02T16:35:14.464Z","phase":"","brief_title":"SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry","source_id_and_acronym":"NCT03452774","lead_sponsor":"Massive Bio, Inc.","biomarkers":" EGFR • HER-2 • PD-L1 • KRAS • BRAF • ER • ALK • TP53 • TMB • FLT3 • ABL1 • NRAS • BRCA1 • BRCA2 • FGFR2 • PTEN • ROS1 • IDH1 • NTRK1 • BCL2 • IDH2 • NTRK3 • NTRK2 • STK11 • NPM1 • HRAS • DNMT3A • ERBB3 • RB1 • CLDN18 • PDGFRA • NF1 • JAK2 • NRG1 • POLE • AKT1 • PD-1 • CCND1 • MCL1 • KDR • PBRM1 • BAP1 • VEGFA • BCL6 • PDGFRB • PTCH1 • FGFR4 • MSH6 • CDK4 • MSH2 • CTNNB1 • MAP2K2 • FBXW7 • WT1 • ATRX • BRCA • RAF1 • TSC2 • CHEK2 • PD-L2 • ERBB4 • JAK1 • FANCA • TSC1 • MDM4 • POLD1 • CDK6 • CEBPA • PARP1 • AURKA • JAK3 • RICTOR • CHEK1 • GATA6 • MSH3 • TGFBR2 • GNAS • MYCL • AKT2 • CCND2 • CCND3 • CSF1R • MAP3K1 • ERCC4 • HDAC1 • PRDM1 • ZNF217 • CDKN1A • GATA3 • PARP2 • PARP3 • SDHA • ACVR1B • ZNF703","pipe":" | ","alterations":" HER-2 mutation • BAP1 mutation • AKT1 mutation • FGFR3 fusion • JAK3 mutation","tags":["EGFR • HER-2 • PD-L1 • KRAS • BRAF • ER • ALK • TP53 • TMB • FLT3 • ABL1 • NRAS • BRCA1 • BRCA2 • FGFR2 • PTEN • ROS1 • IDH1 • NTRK1 • BCL2 • IDH2 • NTRK3 • NTRK2 • STK11 • NPM1 • HRAS • DNMT3A • ERBB3 • RB1 • CLDN18 • PDGFRA • NF1 • JAK2 • NRG1 • POLE • AKT1 • PD-1 • CCND1 • MCL1 • KDR • PBRM1 • BAP1 • VEGFA • BCL6 • PDGFRB • PTCH1 • FGFR4 • MSH6 • CDK4 • MSH2 • CTNNB1 • MAP2K2 • FBXW7 • WT1 • ATRX • BRCA • RAF1 • TSC2 • CHEK2 • PD-L2 • ERBB4 • JAK1 • FANCA • TSC1 • MDM4 • POLD1 • CDK6 • CEBPA • PARP1 • AURKA • JAK3 • RICTOR • CHEK1 • GATA6 • MSH3 • TGFBR2 • GNAS • MYCL • AKT2 • CCND2 • CCND3 • CSF1R • MAP3K1 • ERCC4 • HDAC1 • PRDM1 • ZNF217 • CDKN1A • GATA3 • PARP2 • PARP3 • SDHA • ACVR1B • ZNF703"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 mutation • BAP1 mutation • AKT1 mutation • FGFR3 fusion • JAK3 mutation"],"overall_status":"Recruiting","enrollment":" Enrollment 50000","initiation":"Initiation: 01/01/2018","start_date":" 01/01/2018","primary_txt":" Primary completion: 12/01/2026","primary_completion_date":" 12/01/2026","study_txt":" Completion: 06/01/2027","study_completion_date":" 06/01/2027","last_update_posted":"2024-03-15"},{"id":"6d4a3258-2b1b-4296-b36c-80ae974d4943","acronym":"","url":"https://clinicaltrials.gov/study/NCT04501614","created_at":"2021-01-18T21:33:45.485Z","updated_at":"2024-07-02T16:35:16.674Z","phase":"Phase 1/2","brief_title":"A Study of Ponatinib With Chemotherapy in Children, Teenagers, and Adults With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia","source_id_and_acronym":"NCT04501614","lead_sponsor":"Takeda","biomarkers":" ABL1 • BCR • IGH • PDGFRB • CSF1R • PIAS4","pipe":" | ","alterations":" BCR-ABL1 fusion • BCR-ABL1 T315I • ABL1 T315I • BCR-ABL1 mutation","tags":["ABL1 • BCR • IGH • PDGFRB • CSF1R • PIAS4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCR-ABL1 fusion • BCR-ABL1 T315I • ABL1 T315I • BCR-ABL1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • Iclusig (ponatinib) • cyclophosphamide"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 68","initiation":"Initiation: 02/24/2021","start_date":" 02/24/2021","primary_txt":" Primary completion: 12/19/2024","primary_completion_date":" 12/19/2024","study_txt":" Completion: 01/04/2027","study_completion_date":" 01/04/2027","last_update_posted":"2024-03-04"},{"id":"74d0474d-8a4d-4196-856a-9f95d19d924e","acronym":"BIOVAS","url":"https://clinicaltrials.gov/study/NCT04072042","created_at":"2021-01-18T19:56:06.263Z","updated_at":"2024-07-02T16:35:35.004Z","phase":"Phase 2","brief_title":"BIOmarker Driven Trial of VEGFR2 Inhibitor in Advanced Sarcoma","source_id_and_acronym":"NCT04072042 - BIOVAS","lead_sponsor":"Ruijin Hospital","biomarkers":" KDR • CSF1R","pipe":"","alterations":" ","tags":["KDR • CSF1R"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AiTan (rivoceranib)"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 08/31/2019","start_date":" 08/31/2019","primary_txt":" Primary completion: 02/25/2024","primary_completion_date":" 02/25/2024","study_txt":" Completion: 05/25/2024","study_completion_date":" 05/25/2024","last_update_posted":"2023-10-03"},{"id":"f70ef90a-fdc9-405b-b396-50a810ed6ef5","acronym":"","url":"https://clinicaltrials.gov/study/NCT05273099","created_at":"2022-03-10T14:58:06.191Z","updated_at":"2024-07-02T16:36:13.173Z","phase":"","brief_title":"Molecular Biomarkers Predicting Early Development of Endometrial Carcinoma","source_id_and_acronym":"NCT05273099","lead_sponsor":"Università degli Studi di Ferrara","biomarkers":" EGFR • HER-2 • KRAS • BRAF • ALK • TP53 • PIK3CA • FLT3 • ABL1 • NRAS • FGFR2 • PTEN • IDH1 • IDH2 • FGFR3 • FGFR1 • STK11 • NPM1 • HRAS • CDKN2A • RB1 • PDGFRA • NOTCH1 • JAK2 • GNAQ • AKT1 • KDR • MLH1 • GNA11 • PTPN11 • SMAD4 • CTNNB1 • FBXW7 • CDH1 • SMARCB1 • ERBB4 • JAK3 • GNAS • CSF1R • HNF1A","pipe":" | ","alterations":" JAK3 mutation","tags":["EGFR • HER-2 • KRAS • BRAF • ALK • TP53 • PIK3CA • FLT3 • ABL1 • NRAS • FGFR2 • PTEN • IDH1 • IDH2 • FGFR3 • FGFR1 • STK11 • NPM1 • HRAS • CDKN2A • RB1 • PDGFRA • NOTCH1 • JAK2 • GNAQ • AKT1 • KDR • MLH1 • GNA11 • PTPN11 • SMAD4 • CTNNB1 • FBXW7 • CDH1 • SMARCB1 • ERBB4 • JAK3 • GNAS • CSF1R • HNF1A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e JAK3 mutation"],"overall_status":"Recruiting","enrollment":" Enrollment 8","initiation":"Initiation: 03/01/2022","start_date":" 03/01/2022","primary_txt":" Primary completion: 03/01/2023","primary_completion_date":" 03/01/2023","study_txt":" Completion: 12/01/2023","study_completion_date":" 12/01/2023","last_update_posted":"2022-04-12"},{"id":"fc773c10-831d-4093-bf18-8c93ac9d8441","acronym":"","url":"https://clinicaltrials.gov/study/NCT00699907","created_at":"2021-01-18T02:37:00.384Z","updated_at":"2024-07-02T16:37:08.718Z","phase":"Phase 2a","brief_title":"Effect of Flutamide on Biomarkers in Blood and Tissue Samples From Patients at High Risk of Ovarian Cancer","source_id_and_acronym":"NCT00699907","lead_sponsor":"University of Arizona","biomarkers":" BRCA1 • BRCA2 • ERBB4 • CSF1R","pipe":" | ","alterations":" BRCA2 mutation • HER-2 expression • CSF1 expression • ERBB4 expression","tags":["BRCA1 • BRCA2 • ERBB4 • CSF1R"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation • HER-2 expression • CSF1 expression • ERBB4 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e flutamide"],"overall_status":"Completed","enrollment":" Enrollment 127","initiation":"Initiation: 01/01/2005","start_date":" 01/01/2005","primary_txt":" Primary completion: 11/01/2012","primary_completion_date":" 11/01/2012","study_txt":" Completion: 11/01/2014","study_completion_date":" 11/01/2014","last_update_posted":"2018-07-24"},{"id":"7a5d5274-188b-454f-a274-136cb9718498","acronym":"","url":"https://clinicaltrials.gov/study/NCT01494688","created_at":"2021-01-18T06:15:43.986Z","updated_at":"2024-07-02T16:37:12.988Z","phase":"Phase 1a/1b","brief_title":"A Study of RO5509554 as Monotherapy and in Combination With Paclitaxel in Participants With Advanced Solid Tumors","source_id_and_acronym":"NCT01494688","lead_sponsor":"Hoffmann-La Roche","biomarkers":" CD163 • CD68 • CSF1R","pipe":" | ","alterations":" CD163 expression","tags":["CD163 • CD68 • CSF1R"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD163 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • emactuzumab (RG7155)"],"overall_status":"Completed","enrollment":" Enrollment 217","initiation":"Initiation: 12/20/2011","start_date":" 12/20/2011","primary_txt":" Primary completion: 02/07/2018","primary_completion_date":" 02/07/2018","study_txt":" Completion: 02/07/2018","study_completion_date":" 02/07/2018","last_update_posted":"2018-03-16"},{"id":"560d1c05-5369-4204-a6a9-9952268adb6a","acronym":"SIGNATURE","url":"https://clinicaltrials.gov/study/NCT01831726","created_at":"2021-01-18T08:08:43.044Z","updated_at":"2024-07-02T16:37:24.306Z","phase":"Phase 2","brief_title":"Dovitinib for Patients With Tumor Pathway Activations Inhibited by Dovitinib","source_id_and_acronym":"NCT01831726 - SIGNATURE","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" FLT3 • NTRK1 • KDR • PDGFRB • CSF1R","pipe":"","alterations":" ","tags":["FLT3 • NTRK1 • KDR • PDGFRB • CSF1R"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e dovitinib (TKI258)"],"overall_status":"Completed","enrollment":" Enrollment 80","initiation":"Initiation: 08/01/2013","start_date":" 08/01/2013","primary_txt":" Primary completion: 12/01/2015","primary_completion_date":" 12/01/2015","study_txt":" Completion: 12/01/2015","study_completion_date":" 12/01/2015","last_update_posted":"2017-03-20"}]